Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Kanamycin Sulfate

FDA-approved product (capsule, oral), marketed as Kanamycin, Kanamycin Sulfate, Kantrex and 1 more.

Registered studies
50+
Lab records
73
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Kanamycin Sulfate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Eye infection

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Antibiotics; Other aminoglycosides
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01GB04; WHO ATC A07AA08; WHO ATC S01AA24

Repurposing investigation

Kanamycin Sulfate is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA6.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli4.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae63.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis78.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 1 of 11 lab records
  • E. coli: measured active in 9 of 24 lab records
  • K. pneumoniae: measured active in 4 of 11 lab records
  • M. tuberculosis: measured active in 26 of 27 lab records
Open Kanamycin Sulfate in ChEMBL Registered studies below
Show the 73 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Kanamycin Sulfate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial

    NCT07485010 · start 2027-04

    Registered record
    Registry ID
    NCT07485010
    Conditions
    Mycobacterium Abscessus Pulmonary Disease; Mycobacterium Abscessus Infection; Non-Tuberculous Mycobacterial (NTM) Infections; Non-Tuberculous Mycobacteria Pulmonary Disease
    Interventions
    Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours); Ceftriaxone for Injection; Amoxicillin; Azithromcyin; clarithromycin; Clofazimine; Ethambutol; Amikacin Injection; tigecycline; Imipenem + Cilastatin; Cefoxitin; Amikacin (Inhalation); linezolid; Trimethoprim / Sulfamethoxazole; Doxycycline; moxifloxacin; bedaquiline; Rifabutin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2027-04
    Completion
    2031-07
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMycobacterium Abscessus Pulmonary Disease; Mycobacterium Abscessus Infection; Non-Tuberculous Mycobacterial (NTM) Infections; Non-Tuberculous Mycobacteria Pulmonary Disease
    InterventionSulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours); Ceftriaxone for Injection; Amoxicillin; Azithromcyin +14 more
    PhasePhase 2
    Registry statusNot yet recruiting

  • Potentiated Aminoglycosides in Postoperative Urinary Tract Infection Prophylaxis

    NCT05761405 · start 2024-01-16

    Registered record
    Registry ID
    NCT05761405
    Conditions
    Urinary Tract Infections; Urological System Complication of Procedure
    Interventions
    mannitol-enhanced aminoglycoside; Ceftriaxon; Amikacin
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Unknown
    Start
    2024-01-16
    Completion
    2026-04-15
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infections; Urological System Complication of Procedure
    Interventionmannitol-enhanced aminoglycoside; Ceftriaxon; Amikacin
    PhaseEarly phase 1
    Registry statusUnknown

  • Clinical Outcomes of Inhaled Amikacin in Ventilator Associated Pneumonia

    NCT07369336 · start 2024-01-05

    Registered record
    Registry ID
    NCT07369336
    Conditions
    Ventilator Associated Pneumonia ( VAP)
    Interventions
    Amikacin (Inhalation); Standard-of-Care Intravenous Antibiotics
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2024-01-05
    Completion
    2025-09-30
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVentilator Associated Pneumonia ( VAP)
    InterventionAmikacin (Inhalation); Standard-of-Care Intravenous Antibiotics
    PhasePhase 4
    Registry statusCompleted

  • Tobradex as Intracanal Medicament

    NCT07332936 · start 2023-07-01

    Registered record
    Registry ID
    NCT07332936
    Conditions
    Symptomatic Irreversible Pulpitis; Postoperative Endodontic Pain Following Emergency Root Canal Treatment
    Interventions
    Calcium Hydroxide (Ca(OH)2); Tobramycin + Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2023-07-01
    Completion
    2024-06-30
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSymptomatic Irreversible Pulpitis; Postoperative Endodontic Pain Following Emergency Root Canal Treatment
    InterventionCalcium Hydroxide (Ca(OH)2); Tobramycin + Dexamethasone
    PhaseNot applicable
    Registry statusCompleted

  • Single Dose Amikacin for Uncomplicated Cystitis in the ED: A Feasibility Study

    NCT05227937 · start 2022-09-21

    Registered record
    Registry ID
    NCT05227937
    Conditions
    Urinary Tract Infections
    Interventions
    Amikacin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2022-09-21
    Completion
    2026-12-31
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infections
    InterventionAmikacin
    PhaseNot recorded
    Registry statusRecruiting

  • Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia

    NCT04948463 · start 2021-11-15

    Registered record
    Registry ID
    NCT04948463
    Conditions
    Febrile Neutropenia
    Interventions
    Piperacillin and Tazobactam for Injection; Cefepime Injection; Ceftazidime Injection; Vancomycin Injection; Amikacin Injection; Ciprofloxacin; Piperacillin and Tazobactam for Injection; Cefepime Injection; Ceftazidime Injection; Vancomycin Injection; Amikacin Injection; Ciprofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-11-15
    Completion
    2025-12-17
    Enrolment
    55

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFebrile Neutropenia
    InterventionPiperacillin and Tazobactam for Injection; Cefepime Injection; Ceftazidime Injection; Vancomycin Injection +8 more
    PhasePhase 4
    Registry statusCompleted

  • Acute Application of Antibiotic Powder in Open Fracture Wounds

    NCT04872400 · start 2021-06-14

    Registered record
    Registry ID
    NCT04872400
    Conditions
    Fractures, Open; Wounds and Injuries--Infections; Anti-Bacterial Agents; Fractures, Bone; Extremity Fracture Lower; Extremity Fractures Upper
    Interventions
    Vancomycin; Tobramycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-06-14
    Completion
    2023-09-30
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFractures, Open; Wounds and Injuries--Infections; Anti-Bacterial Agents; Fractures, Bone +2 more
    InterventionVancomycin; Tobramycin
    PhasePhase 4
    Registry statusCompleted

  • Evaluation of a New Strategy for Protocolized Antibiotic Care for Severe Open Fractures: SEXTANT 2

    NCT04678154 · start 2021-05-07

    Registered record
    Registry ID
    NCT04678154
    Conditions
    Post Operative Surgical Site Infection
    Interventions
    Standard of care; Vancomycin and Tobramycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2021-05-07
    Completion
    2029-03-31
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost Operative Surgical Site Infection
    InterventionStandard of care; Vancomycin and Tobramycin
    PhasePhase 3
    Registry statusRecruiting

  • Pharmacokinetics of Amikacin and Cefuroxime in Critically Ill Patients.

    NCT04470973 · start 2020-07-15

    Registered record
    Registry ID
    NCT04470973
    Conditions
    Sepsis; Septic Shock; Infection, Bacterial; Critically Ill
    Interventions
    Cefuroxime; Amikacin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2020-07-15
    Completion
    2023-12-15
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSepsis; Septic Shock; Infection, Bacterial; Critically Ill
    InterventionCefuroxime; Amikacin
    PhaseNot recorded
    Registry statusUnknown

  • To Study Efficacy and Safety of Tobradex Eye Drop Suspension vs Tobramycin/Dexamethasone Ophthalmic Suspension

    NCT03975374 · start 2019-06-15

    Registered record
    Registry ID
    NCT03975374
    Conditions
    Blepharo Conjunctivitis
    Interventions
    Tobramycin/dexamethasone opthalmic solution; Tobradex Opthalmic Solution
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Unknown
    Start
    2019-06-15
    Completion
    2020-06-30
    Enrolment
    5,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBlepharo Conjunctivitis
    InterventionTobramycin/dexamethasone opthalmic solution; Tobradex Opthalmic Solution
    PhaseEarly phase 1
    Registry statusUnknown

  • Antibiotic Elution in Total Knee Arthroplasty

    NCT03928522 · start 2019-01-28

    Registered record
    Registry ID
    NCT03928522
    Conditions
    Total Knee Replacement
    Interventions
    hand mixed vancomycin; hand mixed tobramycin; pre-mixed tobramycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-01-28
    Completion
    2019-09-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTotal Knee Replacement
    Interventionhand mixed vancomycin; hand mixed tobramycin; pre-mixed tobramycin
    PhasePhase 4
    Registry statusCompleted

  • Research of the Consequences on the Digestive Tract Following the Proposed Treatments for a Urinary Infection in Children

    NCT03825874 · start 2019-01-19

    Registered record
    Registry ID
    NCT03825874
    Conditions
    Urinary Tract Infections; Urinary Tract Infections in Children
    Interventions
    Amikacin; usual antibiotic treatment
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2019-01-19
    Completion
    2026-07
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infections; Urinary Tract Infections in Children
    InterventionAmikacin; usual antibiotic treatment
    PhaseNot recorded
    Registry statusRecruiting

  • Topical Antibiotics in Chronic Rhinosinusitis

    NCT03673956 · start 2018-09-26

    Registered record
    Registry ID
    NCT03673956
    Conditions
    Chronic Rhinosinusitis (Diagnosis)
    Interventions
    Mupirocin; Tobramycin; Levofloxacin; Vancomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2018-09-26
    Completion
    2021-02-01
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Rhinosinusitis (Diagnosis)
    InterventionMupirocin; Tobramycin; Levofloxacin; Vancomycin
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Levo-Dexa vs. Tobra+Dexa for Prevention and Treatment of Inflammation and Prevention of Infection in Cataract Surgery

    NCT03739528 · start 2018-09-03

    Registered record
    Registry ID
    NCT03739528
    Conditions
    Cataract
    Interventions
    Levofloxacin + dexamethasone followed by dexamethasone; Tobramycin + Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-09-03
    Completion
    2018-12-19
    Enrolment
    808

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCataract
    InterventionLevofloxacin + dexamethasone followed by dexamethasone; Tobramycin + Dexamethasone
    PhasePhase 3
    Registry statusCompleted

  • Raja Isteri Pengiran Anak Saleha Appendicitis Treatment Without Operation

    NCT03169114 · start 2017-11-01

    Registered record
    Registry ID
    NCT03169114
    Conditions
    Appendicitis; Surgery
    Interventions
    Amikacin Injection; Appendicectomy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2017-11-01
    Completion
    2020-06-30
    Enrolment
    81

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAppendicitis; Surgery
    InterventionAmikacin Injection; Appendicectomy
    PhaseNot applicable
    Registry statusTerminated